These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12374247)

  • 1. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
    Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP
    Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
    Tadrous M; Wong L; Mamdani MM; Juurlink DN; Krahn MD; Lévesque LE; Cadarette SM
    Osteoporos Int; 2014 Apr; 25(4):1225-35. PubMed ID: 24287510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
    Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B
    Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S; Pavelka K; Cline GA; Hosterman MA; Barton IP; Cohen SB; Bensen WG
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
    Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
    Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA; Rizzoli R; Roman-Ivorra J; Lipschitz S; Verbruggen N; Gaines KA; Melton ME
    Curr Med Res Opin; 2004 May; 20(5):699-705. PubMed ID: 15140336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment with bisphosphonates: daily or once-weekly oral administration and intravenous injection].
    Kitahama S; Ishii T; Wada S
    Clin Calcium; 2005 Apr; 15(4):649-54. PubMed ID: 15802779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.
    Morden NE; Munson JC; Smith J; Mackenzie TA; Liu SK; Tosteson AN
    Osteoporos Int; 2015 Feb; 26(2):663-72. PubMed ID: 25349053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New development in bisphosphonate treatment. Bisphosphonates and gastrointestinal adverse effects].
    Miki T; Masaki H
    Clin Calcium; 2009 Jan; 19(1):91-7. PubMed ID: 19122269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
    Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
    Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
    Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
    J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate adverse effects, lessons from large databases.
    Abrahamsen B
    Curr Opin Rheumatol; 2010 Jul; 22(4):404-9. PubMed ID: 20473174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.